-
1
Inflammatory bowel diseases (IBD) exhibit significant heterogeneity in disease course and treatment response, necessitating personalized management strategies.
-
2
Emerging biomarkers, including integrin αvβ6 antibodies and metabolic indices, show promise for improving diagnosis and prognosis in IBD.
-
3
Predictive biomarkers, such as stool TIMP-2 levels, may help identify patients at risk for severe disease progression in Crohn's disease.
-
4
The integration of multi-omics and AI technologies is transforming IBD research, enhancing disease stratification and therapeutic personalization.
-
5
Challenges remain in data standardization and validation, but advancements in biomarkers and AI hold potential for improved IBD management.
